PMID- 2828684
OWN - NLM
STAT- MEDLINE
DCOM- 19880318
LR  - 20200724
IS  - 0022-538X (Print)
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Linking)
VI  - 62
IP  - 3
DP  - 1988 Mar
TI  - Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell 
      recognition in B-cell lines infected with transforming (B95.8) or nontransforming 
      (P3HR1) virus strains.
PG  - 894-901
AB  - Epstein-Barr virus (EBV)-negative Burkitt's lymphoma (BL) cell lines have been 
      converted to EBV genome positivity by in vitro infection with the transforming 
      EBV strain B95.8 and with the nontransforming mutant strain P3HR1, which has a 
      deletion in the gene encoding the nuclear antigen EBNA2. These B95.8- and 
      P3HR1-converted lines have been compared for their patterns of expression of EBV 
      latent genes (i.e., those viral genes constitutively expressed in all 
      EBV-transformed lines of normal B-cell origin) and for their recognition by 
      EBV-specific cytotoxic T lymphocytes (CTLs), in an effort to identify which 
      latent gene products provide target antigens for the T-cell response. 
      B95.8-converted lines on several different EBV-negative BL-cell backgrounds all 
      showed detectable expression of the nuclear antigens EBNA1, EBNA2, and EBNA3 and 
      of the latent membrane protein (LMP); such converts were also clearly recognized 
      by EBV-specific CTL preparations with restriction through selected human 
      leukocyte antigen (HLA) class I antigens on the target cell surface. The 
      corresponding P3HR1-converted lines (lacking an EBNA2 gene) expressed EBNA1 and 
      EBNA3 but, surprisingly, showed no detectable LMP; furthermore, these converts 
      were not recognized by EBV-specific CTLs. Such differences in T-cell recognition 
      were not due to any differences in expression of the relevant HLA-restricting 
      determinants between the two types of convert, as shown by binding of specific 
      monoclonal antibodies and by the susceptibility of both B95.8 and P3HR1 converts 
      to allospecific CTLs directed against these same HLA molecules. The results 
      suggest that in the normal infectious cycle, EBNA2 may be required for subsequent 
      expression of LMP and that both EBNA2 and LMP (but not EBNA1 or EBNA3) may 
      provide target antigens for the EBV-specific T-cell response.
FAU - Murray, R J
AU  - Murray RJ
AD  - Department of Cancer Studies, University of Birmingham, United Kingdom.
FAU - Young, L S
AU  - Young LS
FAU - Calender, A
AU  - Calender A
FAU - Gregory, C D
AU  - Gregory CD
FAU - Rowe, M
AU  - Rowe M
FAU - Lenoir, G M
AU  - Lenoir GM
FAU - Rickinson, A B
AU  - Rickinson AB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
RN  - 0 (Antigens, Viral)
RN  - 0 (Epstein-Barr Virus Nuclear Antigens)
SB  - IM
MH  - Antigens, Viral/genetics/immunology/physiology
MH  - B-Lymphocytes/immunology/*microbiology
MH  - Burkitt Lymphoma/pathology
MH  - Cell Line
MH  - *Cell Transformation, Viral
MH  - Epstein-Barr Virus Nuclear Antigens
MH  - *Gene Expression Regulation
MH  - Herpesvirus 4, Human/genetics/pathogenicity/*physiology
MH  - Humans
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured/immunology/microbiology
PMC - PMC253648
EDAT- 1988/03/01 00:00
MHDA- 1988/03/01 00:01
PMCR- 1988/03/01
CRDT- 1988/03/01 00:00
PHST- 1988/03/01 00:00 [pubmed]
PHST- 1988/03/01 00:01 [medline]
PHST- 1988/03/01 00:00 [entrez]
PHST- 1988/03/01 00:00 [pmc-release]
AID - 10.1128/JVI.62.3.894-901.1988 [doi]
PST - ppublish
SO  - J Virol. 1988 Mar;62(3):894-901. doi: 10.1128/JVI.62.3.894-901.1988.